New data presented at EULAR 2025 highlighted sustained 3-year outcomes for Bimzelx (bimekizumab) across PsA and axial spondyloarthritis. In the BE COMPLETE and BE MOBILE trials, over half of patients achieved and maintained ACR50 or ASAS40 responses. Swollen joint count elimination and PASI 100 rates remained high, demonstrating comprehensive, multi-domain control. The dual inhibition of IL-17A and IL-17F continues to show promise as a long-term strategy, particularly in patients with prior TNFi exposure or severe skin involvement. These results reinforce Bimzelx's competitive position in the IL-17 space, especially as durable disease control becomes a higher priority in treatment decision-making.

Citation: https://www.ucb.com/newsroom/press-releases/article/bimzelxr-bimekizumab-three-year-data-at-eular-2025-showed-lasting-efficacy-and-control-of-inflammation-in-psoriatic-arthritis-and-axial-spondyloarthritis

Implication: Bimzelx continues to prove its value for long-term control in patients needing skin-joint overlap management.